Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of RPH-104 in Healthy Subjects
NCT02667639Phase 1Completed
- Sponsor
- R-Pharm
- Start
- Jan 2016
- Primary completion
- Jun 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic recurrent pericarditis (IRP), Familial Mediterranean fever (FMF), acute myocardial infarction (AMI) and 1 more comparing Treatment (RPH-104) with Placebo (2 arms). Primary endpoints: Adverse Events, Serious Adverse Events and 5 more. Started Jan 2016; status: completed.
02
Drugs
goflikicept
03
Conditions
idiopathic recurrent pericarditis (IRP)Familial Mediterranean fever (FMF)acute myocardial infarction (AMI)gout
Beyond the preview
Go deeper on NCT02667639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667639.